Krystal Biotech, Inc. (KRYS) Return on equity 2021–2025
Krystal Biotech, Inc. (KRYS) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
16.8%FY2025 · since FY2021: -11.7% → 16.8%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 16.8% | +7.4 pp |
| FY2024 | 9.4% | +8.0 pp |
| FY2023 | 1.4% | +28.2 pp |
| FY2022 | -26.8% | -15.1 pp |
| FY2021 | -11.7% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More KRYS financial trends
KRYS RevenueKRYS Net incomeKRYS Net marginKRYS Gross profitKRYS Gross marginKRYS Operating incomeKRYS Operating marginKRYS Operating cash flowKRYS Free cash flowKRYS Capital expendituresKRYS Stock buybacksKRYS Dividends paidKRYS Total assetsKRYS Total liabilitiesKRYS Shareholders’ equityKRYS overview →